64010-37-3

Basic information

• Product Name: 1-Chloro-4-(3-chloropropoxy)benzene
• Synonyms: 1-Chloro-4-(3-chloropropoxy)benzene
• CAS NO: 64010-37-3
• Molecular Weight: 205.084
• Mol File: 64010-37-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Chloro-4-(3-chloropropoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Chloro-4-(3-chloropropoxy)benzene(64010-37-3)
• EPA Substance Registry System: 1-Chloro-4-(3-chloropropoxy)benzene(64010-37-3)

Safety Data

• Hazardous Substances Data: 64010-37-3(Hazardous Substances Data)

Usage

Type of compound

Chlorinated aromatic compound

Uses

Intermediate in the synthesis of pharmaceuticals and agrochemicals

Physical state

Colorless liquid

Boiling point

289.5°C

Density

1.279 g/cm3 at 25°C

Hazardous properties

Harmful if swallowed, inhaled, or absorbed through the skin

Potential health effects

Irritation to the respiratory system and skin

Environmental hazard

Toxicity to aquatic organisms

Safety measures

Handle and use with proper precautions to minimize risks to human health and the environment

Upstream product

• 142-28-9 1,3-Dichloropropane 
• 106-48-9 4-chloro-phenol 
• 109-70-6 1.3-chlorobromopropane 

Downstream Products

• 99059-49-1 (4-chloro-2-chloromethyl-phenyl)-(3-chloro-propyl)-ether 
• 1197837-75-4 (1E)-N-[3-(4-chlorophenoxy)propoxy]-2-(1H-benzimidazol-1-yl)-1-phenylethanimine 
• 1197837-82-3 9-[(2E)-2-{[3-(4-chlorophenoxy)propoxy]imino}-2-phenylethyl]-9H-purin-6-amine 
• 64009-40-1 5-(4-Chloro-phenoxy)-2-(2,4-dichloro-phenyl)-pentanoic acid methyl ester 
• 64009-62-7 2-(2,4-Dichlorphenyl)-5-(4-chlorphenoxy)-pentanol 
• 69183-02-4 {4-[3-(4-Chloro-phenoxy)-propoxy]-phenyl}-(4-phenoxy-phenoxy)-acetic acid methyl ester 
• 69183-06-8 (4-Benzyloxy-phenoxy)-{4-[3-(4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid methyl ester 
• 69183-07-9 (4-Benzyloxy-phenoxy)-{4-[3-(4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid 
• 69183-21-7 {4-[3-(4-Chloro-phenoxy)-propoxy]-phenyl}-(4-trifluoromethyl-phenoxy)-acetic acid methyl ester 
• 69183-68-2 {4-[3-(4-Chloro-phenoxy)-propoxy]-phenyl}-(3-trifluoromethyl-phenoxy)-acetic acid 
• 69183-08-0 {4-[3-(4-Chloro-phenoxy)-propoxy]-phenyl}-(4-cyano-phenoxy)-acetic acid methyl ester 
• 69183-04-6 {4-[3-(4-Chloro-phenoxy)-propoxy]-phenyl}-(indan-5-yloxy)-acetic acid methyl ester 
• 69183-12-6 (4-tert-Butyl-2-chloro-phenoxy)-{4-[3-(4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid 
• 69182-99-6 (4-tert-Butyl-phenoxy)-{4-[3-(4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid methyl ester 

Relevant articles and documents

Synthesis and evaluation of aryl substituted propyl piperazines for potential atypical antipsychotic activity

Background: Schizophrenia is a disorder with complex etiology with hyperdopaminer-gia as the leading underlying cause. Atypical antipsychotics are the agents which do not give rise to significant extrapyramidal side effects and are more effective against negative symptoms of schizophrenia. Introduction: A new series of chloro-substituted substituted aryloxypiperazine derivatives and their indole based derivatives was designed and evaluated for atypical antipsychotic activity based on established models for combined dopaminergic and serotonergic antagonism. Method: The present series of compounds were designed based on 3D similarity studies, synthesized and evaluated for atypical antipsychotic activity in animal models for combined dopaminer-gic and serotonergic antagonism. The blood-brain barrier penetration potential was assessed from theoretical log BB values computed through an online software program. Results: Theoretical ADME profiling of the designed compounds based on selected physicochem-ical parameters suggested excellent compliance with Lipinski’s rules. The log BB values obtained for the compounds suggested a good potential for brain permeation. Indole substitution contributed towards an improved efficacy over aryloxy analogs. Lead compounds showed a potential for combined dopaminergic and serotonergic antagonism. Conclusion: The 5-methoxy indole based compounds 16 and 17 were identified as the lead compounds displaying a potential atypical antipsychotic profile.

Copper-Catalyzed Regioselective Hydroalkylation of 1,3-Dienes with Alkyl Fluorides and Grignard Reagents

Copper complexes generated in situ from CuCl2, alkyl Grignard reagents, and 1,3-dienes play important roles as catalytic active species for the 1,2-hydroalkylation of 1,3-dienes by alkyl fluorides through C-F bond cleavage. The alkyl group is introduced to an internal carbon atom of the 1,3-diene regioselectively, thus giving rise to the branched terminal alkene product. Making the switch: A copper-hydride species, generated by the treatment of a copper salt with alkyl Grignard reagents, catalyzes the 1,2-hydroalkylation of 1,3-dienes by alkyl fluorides and Grignard reagents. The alkyl group of the alkyl fluoride is selectively introduced to an internal carbon atom of the 1,3-diene and the Grignard reagent acts as hydride source to give the branched terminal alkene, even in the presence of alkenes and alkynes.

Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment

A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: STR1 wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH2 -- or STR2 n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the α carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.